PURPOSE: To estimate the annual incidence, cumulative probability of presumed urinary tract infection (UTI) by age, and the social costs. METHODS: Analysis of a random digit dialing survey of 2000 women in the United States. RESULTS: 10.8 percent (95% CI: 9.4, 12.1%) of women aged 18 and older reported at least one presumed UTI during the past 12 months, with the majority of the cases occurring among women with a history of two or more UTI episodes in their life. We estimate that by age 24, one-third of women will have at least one physician-diagnosed UTI that was treated with prescription medication. Overall, an estimated 11.3 million women in the United States had at least one presumed UTI treated with antibiotics in 1995. We estimate the annual cost of UTI cases with prescriptions to be $1.6 billion in 1995. If the costs occurring after 1995 are discounted at 5% annually, the total cost over 20 years has a present value of $25.5 billion. CONCLUSION: If a vaccine were developed that would prevent either initial or recurrent UTI the net benefits to society would be substantial, even at a developmental cost of one billion dollars.
PURPOSE: To estimate the annual incidence, cumulative probability of presumed urinary tract infection (UTI) by age, and the social costs. METHODS: Analysis of a random digit dialing survey of 2000 women in the United States. RESULTS: 10.8 percent (95% CI: 9.4, 12.1%) of women aged 18 and older reported at least one presumed UTI during the past 12 months, with the majority of the cases occurring among women with a history of two or more UTI episodes in their life. We estimate that by age 24, one-third of women will have at least one physician-diagnosed UTI that was treated with prescription medication. Overall, an estimated 11.3 million women in the United States had at least one presumed UTI treated with antibiotics in 1995. We estimate the annual cost of UTI cases with prescriptions to be $1.6 billion in 1995. If the costs occurring after 1995 are discounted at 5% annually, the total cost over 20 years has a present value of $25.5 billion. CONCLUSION: If a vaccine were developed that would prevent either initial or recurrent UTI the net benefits to society would be substantial, even at a developmental cost of one billion dollars.
Authors: Terje Alraek; Liv Inger Fosli Soedal; Siri Urnes Fagerheim; Asbjørn Digranes; Anders Baerheim Journal: Am J Public Health Date: 2002-10 Impact factor: 9.308
Authors: Laura Ferreira; Fernando Sánchez-Juanes; Magdalena González-Avila; David Cembrero-Fuciños; Ana Herrero-Hernández; José Manuel González-Buitrago; Juan Luis Muñoz-Bellido Journal: J Clin Microbiol Date: 2010-04-14 Impact factor: 5.948
Authors: Francis M Hughes; Nivardo P Vivar; James G Kennis; Jeffery D Pratt-Thomas; Danielle W Lowe; Brooke E Shaner; Paul J Nietert; Laura S Spruill; J Todd Purves Journal: Am J Physiol Renal Physiol Date: 2013-11-27
Authors: Matt S Conover; Ségolène Ruer; Joemar Taganna; Vasilios Kalas; Henri De Greve; Jerome S Pinkner; Karen W Dodson; Han Remaut; Scott J Hultgren Journal: Cell Host Microbe Date: 2016-09-22 Impact factor: 21.023